New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.

Scientists at St. Jude Children's Research Hospital have revealed how Fanzor2's divergence from bacterial ancestors may make ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

The treatment, involving the use of donor cells, has shown positive results in patients six months after receiving treatment.

Age impedes the ability of the brain’s stem cells to churn out new cells, but the study’s authors found that reducing the ...

Three patients are in “safe, deep remission” after receiving a CRISPR-Cas9-modified cell therapy for autoimmune disease ...

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...

Jennifer Doudna's gene-editing technology CRISPR can now manipulate populations of microbes. This new field, called precision microbiome editing, could potentially address asthma and Alzheimer's.

About NTLA-2002 Based on Nobel-prize winning CRISPR/Cas9 technology, NTLA-2002 has the potential to become the first one-time treatment for hereditary angioedema (HAE). NTLA-2002 is designed to ...

Scientists at St. Jude Children’s Research Hospital revealed how Fanzor2’s divergence from bacterial ancestors may make it a ...